Literature DB >> 12652159

Nitric oxide, platelet function, myocardial infarction and reperfusion therapies.

David Alonso1, Marek W Radomski.   

Abstract

Platelets play an important role in physiologic hemostasis and pathologic thrombosis that complicate the course of vascular disorders. A number of platelet functions including adhesion, aggregation and recruitment are controlled by nitric oxide (NO) generated by platelets and the endothelial cells. Derangements in this generation may contribute to the pathogenesis of thrombotic complications of vascular disorders. The pharmacologic supplementation of the diseased vasculature with drugs releasing NO may help to restore the hemostatic balance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652159     DOI: 10.1023/a:1022194921040

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  90 in total

1.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.

Authors:  D S Bredt; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 2.  Nitric oxide synthase: aspects concerning structure and catalysis.

Authors:  M A Marletta
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

Review 3.  GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.

Authors:  B S Coller
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

4.  Release of gelatinase A during platelet activation mediates aggregation.

Authors:  G Sawicki; E Salas; J Murat; H Miszta-Lane; M W Radomski
Journal:  Nature       Date:  1997-04-10       Impact factor: 49.962

5.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

6.  Direct electrochemical measurement of nitric oxide released from human platelets.

Authors:  T Malinski; M W Radomski; Z Taha; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1993-07-30       Impact factor: 3.575

7.  Role of platelets in myocardial ischemia-reperfusion injury in dogs.

Authors:  Y Shimada; Y Kutsumi; H Nishio; K Asazuma; H Tada; T Hayashi; T Nakai; K Morioka
Journal:  Jpn Circ J       Date:  1997-03

8.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.

Authors:  W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

9.  Inhibition of nitric oxide limits infarct size in the in situ rabbit heart.

Authors:  V C Patel; D M Yellon; K J Singh; G H Neild; R G Woolfson
Journal:  Biochem Biophys Res Commun       Date:  1993-07-15       Impact factor: 3.575

10.  Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury.

Authors:  R Schulz; R Wambolt
Journal:  Cardiovasc Res       Date:  1995-09       Impact factor: 10.787

View more
  13 in total

Review 1.  Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.

Authors:  Paul Jurasz; David Alonso-Escolano; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

2.  Platelets oxidative stress in Indian patients with ischemic heart disease.

Authors:  Mahdi Garelnabi; Vinod Gupta; Venkatesan Mallika; Jayashree Bhattacharjee
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 3.  The nitric oxide-endothelin-1 connection.

Authors:  David Alonso; Marek W Radomski
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

4.  Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension.

Authors:  Hakan Ekmekçi; Ozlem Balci Ekmekçi; Serap Erdine; Hüseyin Sönmez; Yusup Ataev; Zeynep Oztürk; Ilknur Işler Bütün; Ciğdem Gürel; Mine Kucur; Nurver Turfaner; Turgut Ulutin; Sevim Purisa; Vural Ali Vural
Journal:  J Thromb Thrombolysis       Date:  2008-11-11       Impact factor: 2.300

5.  Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects.

Authors:  J Jose Corbalan; Carlos Medina; Adam Jacoby; Tadeusz Malinski; Marek W Radomski
Journal:  Int J Nanomedicine       Date:  2011-11-09

6.  Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1.

Authors:  J George Groeneweg; Frank J P M Huygen; Claudia Heijmans-Antonissen; Sjoerd Niehof; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2006-11-30       Impact factor: 2.362

Review 7.  Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management.

Authors:  George Groeneweg; Frank J P M Huygen; Terence J Coderre; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2009-09-23       Impact factor: 2.362

8.  Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis.

Authors:  J Jose Corbalan; Carlos Medina; Adam Jacoby; Tadeusz Malinski; Marek W Radomski
Journal:  Int J Nanomedicine       Date:  2012-02-07

9.  Expression of endothelial nitric oxide synthase and endothelin-1 in skin tissue from amputated limbs of patients with complex regional pain syndrome.

Authors:  J George Groeneweg; Claudia Heijmans Antonissen; Frank J P M Huygen; Freek J Zijlstra
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

10.  Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial.

Authors:  George Groeneweg; Frank J P M Huygen; Sjoerd P Niehof; Feikje Wesseldijk; Johannes B J Bussmann; Fabienne C Schasfoort; Dirk L Stronks; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2008-10-20       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.